Company Profile
Beam Therapeutics Stock Price, News & Analysis
- Ticker:
- BEAM
- Exchange:
- NASDAQ
- Sector:
- Biopharma
- Location:
- United States
Stock performance
25.07 USD (-0.12%)
Close
Last updated: July 27, 2026
2.98B USD
Market cap
Why the stock is moving
As of Jul 27, 2026, BEAM was little changed and closed at $25.07. No new same-company headline was identified in the current news window.
Company overview
Business overview
Beam Therapeutics is a gene-editing company focused on base editing and precision correction of genetic mutations.
Geographic Base and Sector Classification
Headquartered in the United States and listed on NASDAQ, Beam sits in advanced gene-editing biotechnology.
Business Model Characteristics
The company combines platform science, preclinical and clinical validation, and the long-term opportunity to edit genes more precisely than older methods.
Position Within the Biotechnology Landscape
Beam is one of the leading base-editing companies, and its stock remains tied to technical validation and clinical momentum.
Future catalysts
Beam has a more tangible path now with BEAM-304 in PKU and BEAM-302 in alpha-1 antitrypsin deficiency. The new liver-targeted program broadens the platform, but the next real test is whether the gene-editing work keeps producing human data that looks good enough to support a deeper development push.
Recent news
The five most recent related feed items are shown below in reverse chronological order.
- 01
Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
NTLA · Source: Intellia
- 02
- 03
Prime Medicine to Present at Goldman Sachs 47th Annual Global Healthcare Conference
PRME · Source: Prime Medicine
- 04
- 05
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.
Frequently Asked Questions
What is the current stock price of Beam Therapeutics (BEAM)?
Beam Therapeutics (BEAM) most recently closed at 25.07 USD, a -0.12% move versus the previous session.
What is the market cap of Beam Therapeutics (BEAM)?
Beam Therapeutics currently has a market capitalization of 2.98B USD on BioPharmSignal.
What does Beam Therapeutics do?
Beam Therapeutics is a gene-editing company focused on base editing and precision correction of genetic mutations.
On which exchange is BEAM stock listed?
Beam Therapeutics (BEAM) is associated with NASDAQ, United States, Biopharma.
What is BEAM-304?
Beam has a more tangible path now with BEAM-304 in PKU and BEAM-302 in alpha-1 antitrypsin deficiency.
Which conditions is Beam Therapeutics targeting with BEAM-304?
Beam Therapeutics is associated with genetic disease based on its company overview and current catalyst commentary.
How does Beam Therapeutics describe recent progress with BEAM-304?
Beam has a more tangible path now with BEAM-304 in PKU and BEAM-302 in alpha-1 antitrypsin deficiency.
What is BEAM-302?
Beam has a more tangible path now with BEAM-304 in PKU and BEAM-302 in alpha-1 antitrypsin deficiency.